TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03234751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous IV infusion of Nesiritide
Description: Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous IV infusion of Nesiritide
Description: Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamp
Description: 48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamp
Description: 48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 48 hours of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 48 hours of placebo.
Study: NCT02839915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo comparator
Study: NCT01631877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin with acenocoumarol
Description: enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection placebo will be given for 5 days along with placebo tablets
Study: NCT02746874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Description: The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated Radiofrequency Ablation (RFA)
Description: The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
Study: NCT02106884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT00765544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot
Description: The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot
Description: The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
Study: NCT04017104

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT
Description: For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-DOTATOC PET/CT
Description: Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-DCFPyL PET/CT
Description: Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
Study: NCT03498365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCDA
Description: Experimental decision support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delphi
Description: Standard support
Study: NCT04139187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training with power and strength exercises
Description: The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks).
Study: NCT03388060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided SWL
Description: Ultrasound guided SWL for radiolucent renal stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dissolution therapy
Description: Alkalinization dissolution therapy for radiolucent renal stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined ultrasound guided SWL and dissolution therapy
Description: Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
Study: NCT02402543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02921698

Intervention type: DEVICE
Intervention: FRED®
Description: Flow Re-Direction Endoluminal Device
Study: NCT03144388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable Stepping Training
Description: Six weeks (20 sessions) of high intensity stepping training in multiple variable environments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variable Non-specific Training
Description: Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
Study: NCT01518777

Intervention type: OTHER
Group type: OTHER
Intervention: Half-dose isotope for NuclearStressTest
Description: Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
Study: NCT00473642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal administered ranibizumab 0.5 mg in 0.05 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal administered ranibizumab 0.5 mg in 0.05 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal administered ranibizumab 0.5 mg in 0.05 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
Study: NCT00982592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01496339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenSCs transplantation
Description: 1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exogenous indulin injection daily
Description: traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
Study: NCT01217866

Intervention type: PROCEDURE
Intervention: Laparoscopic assisted vaginal hysterectomy
Description: Surgical removal of uterus vaginally
Study: NCT04129099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC022F
Description: GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
Study: NCT00089791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection
Study: NCT02879942

Intervention type: OTHER
Intervention: Ultrasound study of the placenta
Description: The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.

Intervention type: OTHER
Intervention: Ultrasound study of the placenta
Description: The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.

Intervention type: OTHER
Intervention: Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test
Study: NCT03186079

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Toilet training
Description: Toilet training has been considered a routine method in treatment of constipation
Study: NCT00645229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
Study: NCT01732133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexfin
Study: NCT04729699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and exercise for TMJ
Description: Aerobic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise at home
Description: Aerobic exercise
Study: NCT01430598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair and Subacromial Decompression
Description: Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair and Subacromial Decompression
Description: Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
Study: NCT01024946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
Study: NCT03822286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-training course
Description: Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support group
Description: A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional classroom teaching course programs
Description: Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
Study: NCT03273868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity low amplitude manipulation
Description: The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
Study: NCT02510976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00853112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 1 mg, single dose (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 2 mg, single dose (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 4 mg, single dose (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 10 mg, single dose (Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: tablet form, 20 mg, single dose (Day 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet form, single dose (Day 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: tablet form, 20 mg, single dose (Day 1)
Study: NCT00429117

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Internet survey lasting 30 to 40 minutes.
Study: NCT02879942

Intervention type: OTHER
Intervention: Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test
Study: NCT00856362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT04547660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
Study: NCT02499094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral-data driven support
Description: Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral-data driven support
Description: Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
Study: NCT01546025

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling
Description: One hour session of brief motivational counseling focused on reduction of heavy drinking.
Study: NCT05063760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic-strength exercise intervention (6-months)
Description: 6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
Study: NCT02655263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Somatropin infusion (Genotropin®)
Study: NCT01546025

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation training
Description: One hour training in relaxation techniques
Study: NCT02066155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parish nurse
Description: On-going support following diabetes self-management education provided by Parish Nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: On-going support following diabetes self-management education provided by a trained person with diabetes
Study: NCT03046706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: post operative voice rest
Description: After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No voice rest
Description: No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
Study: NCT03905278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental guidance
Description: A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.